2017 Apr;43(4):584-594. doi: 10.1080/03639045.2016.1274901. Epub 2017 Jan 8.

Author information

1
a Department of Pharmacy and Pharmacology , Antoni van Leeuwenhoek Hospital/MC Slotervaart , Amsterdam , The Netherlands.
2
b Department of Clinical Pharmacology , the Netherlands Cancer Institute , Amsterdam , the Netherlands.
3
c Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology & Clinical Pharmacology , Utrecht University , Utrecht , the Netherlands.

Abstract

OBJECTIVE:

A novel tablet formulation containing an amorphous solid dispersion (ASD) of elacridar hydrochloride was developed with the purpose to resolve the drug’s low solubility in water and to conduct proof-of-concept clinical studies.

SIGNIFICANCE:

Elacridar is highly demanded for proof-of-concept clinical trials that study the drug’s suitability to boost brain penetration and bioavailability of numerous anticancer agents. Previously, clinical trials with elacridar were performed with a tablet containing elacridar hydrochloride. However, this tablet formulation resulted in poor and unpredictable absorption which was caused by the low aqueous solubility of elacridar hydrochloride.

METHODS:

Twenty four different ASDs were produced and dissolution was compared to crystalline elacridar hydrochloride and a crystalline physical mixture. The formulation with highest dissolution was characterized for amorphicity. Subsequently, a tablet was developed and monitored for chemical/physical stability for 12 months at +15-25 °C, +2-8 °C and -20 °C.

RESULTS:

The ASD powder was composed of freeze dried elacridar hydrochloride-povidone K30-sodium dodecyl sulfate (1:6:1, w/w/w), appeared fully amorphous and resulted in complete dissolution whereas crystalline elacridar hydrochloride resulted in only 1% dissolution. The ASD tablets contained 25 mg elacridar hydrochloride and were stable for at least 12 months at -20 °C.

CONCLUSIONS:

The ASD tablet was considered feasible for proof-of-concept clinical studies and is now used as such.

KEYWORDS:

Elacridar; GF120918; GG918; P-gp; absorption; brain penetration; dissolution; freeze drying; solid dispersion; spray drying

Leave a Reply

Your email address will not be published. Required fields are marked *